UM Ventures engages industry through the development of corporate sponsored research agreements and clinical trial agreements. Sponsored research agreements allow companies to take advantage of UM resources by funding research in UM laboratories by UM scientists. The research project and budget are determined by the company and the UM scientists and the company receives data in exchange for the research funding. When proprietary intellectual property arises out of sponsored research, UM seeks to provide the sponsoring company with rights to develop the intellectual property for commercial purposes via a license agreement.
To connect with the University of Maryland, Baltimore, contact Marco Chacón
Click here to find a collaborator at University of Maryland, Baltimore.
E-mail here to find a collaborator at the University of Maryland, College Park.
Resources at University of Maryland, Baltimore
Faculty entrepreneurs may engage industry in ways other than licensing and new venture formation. The Center for Clinical Trials and Corporate Contracts (CCT) at the University of Maryland, Baltimore develops and negotiates several types of agreements with industry partners:
- Corporate-sponsored Clinical Trial Agreements (CTAs)
- Confidential Disclosure Agreements (CDAs)
- CTA budgets and billing plans that comply with Federal Medicare regulations
- Corporate-sponsored Research Agreements
- Corporate-sponsored Research Services Agreements
- Material Transfer Agreements
The UM Ventures Industry Liaison Office (ILO) provides support to faculty pursuing potential funding/partnering opportunities as well as those faculty already working with industry. Primary services offered include:
- Marketing faculty, research and other capabilities to industry
- Training faculty with respect to developing industry partnerships and working with industry partners
- Assisting faculty in the successful management of industry-sponsored research projects
- Assisting faculty and Senior Management in managing multi-dimensional UMB-industry collaborations
Michael Rollor, Ph.D., M.B.A.
Assistant Vice President Center for Clinical Trials and Corporate Contracts
MedImmune Expands USM Research Collaboration
April 29, 2014
COLLEGE PARK, Md. – The University System of Maryland and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been expanded to include the University of Maryland, College Park and the University of Maryland, Baltimore County.
The collaborators have also announced that they have identified the first five research projects to be undertaken under the expanded agreement. This follows the September 2013 announcement in which MedImmune and UMB announced a five-year, $6 million collaboration to drive novel bioscience research in the state of Maryland.
Click here to read the entire press release.
MedImmune, UMB ink $6 million research partnership
The deal spans five years, with all but $1 million of the bill footed by MedImmune. Under the agreement — the first of several planned for the Maryland biotech firm— MedImmune and UMB will undertake joint projects in the company's "core therapeutic areas," which include oncology, autoimmune and respiratory diseases. UMB is home to the University of Maryland BioPark.
Click here to read full article in Washington Business Journal